A loss of stromal Cav1 also predicts progression to invasive disease in DCIS (ductal carcinoma in situ) patients, suggesting that a loss of Cav1 regulates tumor progression (6). This evidence concerns the gene CAV1 and ductal breast carcinoma in situ.